COPD
During the FP-treatment of COPD patients, FEV1 remained stable,       while FEV1 deteriorated significantly in the placebo group.
During the FP-treatment of  @SUBJECT$  @PREDICAT$  @OBJECT$ , FEV1 remained stable,       while FEV1 deteriorated significantly in the placebo group.